摘要
目的分析探讨阿替普酶和尿激酶治疗心肌梗死的临床疗效。方法选自2016年9月—2017年9月在该院治疗的急性心肌梗死患者104例作为实验对象,随机分成实验组和对照组,每组52例,实验组和对照组分别用阿替普酶和尿激酶治疗,对比两组的治疗效果和并发症情况。结果根据治疗的总有效率来看,实验组94.23%明显要高于对照组84.62%,差异有统计学意义(χ~2=4.15,P<0.05);根据治疗后的并发症情况来看,实验组患者的血管再通率、血管再梗、心律失常、心力衰竭、梗死后心绞痛、死亡等(发病率分别为75.00%、1.92%、25.00%、1.92%、15.39%和5.77%)均要好于对照组(发病率分别为61.54%、5.77%、36.54%、9.62%、21.15%和11.54%),差异有统计学意义(χ~2=1.58、1.26、1.94、2.48、2.76、1.46,P<0.05)。结论阿替普酶在治疗急性心肌梗死的有效率和治疗后并发症上均好于尿激酶,适合临床应用。
Objective To analyze the clinical efficacy of alteplase and urokinase in the treatment of myocardial infarction. Methods A total of 104 patients with acute myocardial infarction who were treated in the hospital from September 2016 to September 2017 were randomly divided into the experimental group and the control group, 52 in each group. The experimental group and the control group were treated with altepl. Enzyme and urokinase treatment, comparing the treatment effect and complications of the two groups. Results According to the total effective rate of treatment, 94.23% of the experimental group was significantly higher than 84.62% of the control group, the different was statistically significant(χ^2=4.15, P<0.05). According to the complications after treatment, In the experimental group, the recanalization rate, revascularization, arrhythmia, heart failure, post-infarction angina, and death incidence rates of 75.00%, 1.92%, 25.00%, 1.92%, 15.39%, and 5.77%, respectively were better than those of the patients. The control group (incidence rate was 61.54%, 5.77%, 36.54%, 9.62%, 21.15%, and 11.54%, respectively), the different was statistically significant(χ^2=1.58, 1.26, 1.94, 2.48, 2.76, 1.46, P<0.05). Conclusion Alteplase is better than urokinase in the treatment of acute myocardial infarction, and is suitable for clinical application.
作者
余西兰
胡征
YU Xi-lan;HU Zheng(Chongqing Traditional Chinese Medicine Orthopaedic Hospital,Chongqing,400010 China)
出处
《系统医学》
2018年第23期22-24,共3页
Systems Medicine
关键词
阿替普酶
尿激酶
急性心肌梗死
临床疗效
Alteplase
Urokinase
Acute myocardial infarction
Clinical efficacy
